Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

Phase 2 clinical study evaluating REGEND001 cell therapy for idiopathic pulmonary fibrosis has completed, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• REGEND001

Snippet

Sponsor: Regend Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED